- Home
- LAB
as 06-20-2025 4:00pm EST
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 372.1M | IPO Year: | 2011 |
| Target Price: | $2.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $2.41 | Next Earning Date: | 07-30-2025 |
| Revenue: | $169,687,000 | Revenue Growth: | 33.86% |
| Revenue Growth (this year): | -2.06% | Revenue Growth (next year): | 12.18% |
Stock Insider Trading Activity of Standard BioTools Inc. (LAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Egholm Michael | LAB | President & CEO | May 23 '25 | Sell | $0.94 | 5,473 | $5,150.09 | 2,741,191 | |
| Kim Hanjoon Alex | LAB | Chief Financial Officer | May 23 '25 | Sell | $0.94 | 1,428 | $1,343.75 | 930,286 | |
| Mackay Sean | LAB | SVP & Chief Business Officer | May 23 '25 | Sell | $0.94 | 13,217 | $12,437.20 | 843,076 | |
| Egholm Michael | LAB | President & CEO | May 22 '25 | Sell | $1.00 | 5,116 | $5,126.23 | 2,741,191 | |
| Kim Hanjoon Alex | LAB | Chief Financial Officer | May 22 '25 | Sell | $1.00 | 1,355 | $1,357.71 | 930,286 | |
| Mackay Sean | LAB | SVP & Chief Business Officer | May 21 '25 | Sell | $1.02 | 25,374 | $25,784.21 | 843,076 | |
| Egholm Michael | LAB | President & CEO | May 20 '25 | Sell | $1.03 | 4,719 | $4,860.57 | 2,741,191 | |
| Kim Hanjoon Alex | LAB | Chief Financial Officer | May 20 '25 | Sell | $1.03 | 1,407 | $1,449.21 | 930,286 |
Latest Standard BioTools Inc. News
LAB Breaking Stock News: Dive into LAB Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
With 48% stake, Standard BioTools Inc. (NASDAQ:LAB) seems to have captured institutional investors' interest
GlobeNewswire
22 days ago
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
Simply Wall St.
a month ago
Standard BioTools First Quarter 2025 Earnings: Beats Expectations
Thomson Reuters StreetEvents
a month ago
Q1 2025 Standard BioTools Inc Earnings Call
GuruFocus.com
a month ago
Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
Zacks
a month ago
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Standard BioTools Reports First Quarter 2025 Financial Results
GuruFocus.com
2 months ago
Standard BioTools Inc (LAB) Q1 2025 Earnings Report Preview: What To Look For
Compare LAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LAB Standard BioTools Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.